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__________________________________________________________________________27 
ABSTRACT  28 
 29 
Streptococcus pneumoniae is a Gram-positive pathogen, which is regularly found in the 30 
upper respiratory tract of healthy individuals. Increased numbers of S. pneumoniae have been 31 
observed colonising the upper respiratory tract of children affected by respiratory tract 32 
infections. Galβ1-4GlcNAcβ1-3Gal has been previously identified as one of the receptors 33 
involved in the adherence and translocation of S. pneumoniae. As this structure is similar to 34 
the milk oligosaccharide lacto-N-neoTetraose, many studies have investigated if free milk 35 
oligosaccharides can inhibit the adhesion of S. pneumoniae to epithelial cells of the 36 
respiratory tract. Here, we demonstrate that bovine oligosaccharides, which were extracted 37 
from demineralised whey, using a combination of membrane filtration and chromatography, 38 
were capable of reducing S. pneumoniae adhesion to pharynx and lung cells in vitro when 39 
tested at physiological concentrations. This study strengthens the potential use of bovine 40 
derived milk oligosaccharides as functional ingredients to reduce the incidence of infectious 41 
diseases. 42 
___________________________________________________________________________ 43 
 44 
 45 
 46 
 47 
 48 
 49 
50 
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1. Introduction 51 
 52 
Respiratory tract infections (RTI) account for almost half of all general practitioner 53 
and hospital visits by infants and young children (Bachrach, Schwarz, & Bachrach, 2003). 54 
The most common infections include acute otitis media, sinusitis and bronchitis. In general, 55 
RTI are caused by either viral or bacterial pathogens and very often as a combination of both. 56 
Bacteria frequently associated with respiratory tract infections include Streptococcus 57 
pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, and Staphylococcus aureus 58 
(Bosch, Biesbroek, Trzcinski, Sanders, & Bogaert, 2013; Pettigrew, Gent, Revai, Patel, & 59 
Chonmaitree, 2008). 60 
Streptococcus pneumoniae is a Gram positive pathogen, which regularly colonises the 61 
upper respiratory tract (URT) of healthy individuals. Carriage of S. pneumoniae is typically 62 
asymptomatic in nature (Bogaert, de Groot, & Hermans, 2004). However, if this bacterium 63 
gains access to the sterile parts of the respiratory tract, the result is a swift inflammatory 64 
response, which in turn causes disease. Elevated S. pneumoniae colonisation has been 65 
recorded in the URT of children suffering from RTI (García-Rodríguez & Martinez, 2002). 66 
Furthermore, the colonisation of the respiratory tract by S. pneumoniae reduces the microbial 67 
diversification of the host; this, in turn, has been linked to an increased risk of respiratory 68 
infections. Infections of the lower respiratory tract of infants and young children is also a 69 
matter of great importance, as pneumonia is one of the leading causes of global infant 70 
mortality. In fact, greater than 30% of pneumonia related deaths are caused by S. pneumoniae 71 
(Rudan, Boschi-Pinto, Biloglav, Mulholland, & Campbell, 2008). 72 
To cause infection, S. pneumoniae must first adhere to human nasopharyngeal 73 
epithelial cells. One of the receptors responsible for the attachment of S. pneumoniae to 74 
human nasopharyngeal epithelial cells is GlcNAcβ1-3Gal (Andersson & Svanborg-Eden, 75 
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1989). This receptor shares similarity with the oligosaccharide lacto-N-neoTetraose, Galβ1-76 
4GlcNAcβ1-3Galβ1-4Glc (LNnT) (Idänpään-Heikkilä et al., 1997). In this respect, several 77 
studies have demonstrated that synthesised oligosaccharides (OS) inhibit the adhesion of S. 78 
pneumoniae to epithelial cells of the respiratory tract. For instance, the pre-exposure of S. 79 
pneumoniae to LNnT and its α2-6-sialylated derivative reduced the pneumococcal load in the 80 
lungs of animal models (Idänpään-Heikkilä et al., 1997). Furthermore, LNnT was reported to 81 
inhibit the adherence of S. pneumoniae to the receptor Galβ1-4GlcNAcβ1-3Gal (Tong, 82 
McIver, Fisher, & DeMaria, 1999). LNnT also provided a protective effect against S. 83 
pneumoniae by preventing pneumonia in rabbits (Idänpään-Heikkilä et al., 1997). Sialylated 84 
oligosaccharide ligands terminating in NeuAcα2-3(or 6)Galβ1 were demonstrated to reduce 85 
the adhesion of S. pneumoniae to human bronchial and tracheal cells (Barthelson, Mobasseri, 86 
Zopf, & Simon, 1998). These studies strongly suggest that free OS such as LNnT, 3’SLNnT, 87 
6’SLNnT, can prevent the adhesion of S. pneumoniae to human epithelial cells. These OS 88 
and several other complex OS are naturally found in breast milk (Kunz, Rudloff, Baier, Klein 89 
& Strobel, 2000). In fact, it is known that infants those who are exclusively breastfed have a 90 
lower incidence of RTI (Wright, Holberg, Martinez, Morgan, & Taussig, 1989). 91 
 However, the protective effects ascribed to human milk oligosaccharides (HMO) are 92 
not available to formula-fed infants. Infant milk formulas are based on bovine milk, which 93 
contains a lower concentration of bovine milk oligosaccharides (BMO; ~0.03 g L-1) 94 
compared to OS in human milk (10–15 g L-1; Kunz et al., 2000). A number of BMO do, 95 
however, share the same structure as certain HMO, which could imply common 96 
functionalities (Barile et al., 2009; Mariño et al., 2011). Therefore, value may lie in extracting 97 
and concentrating BMO with a view to their addition as an active ingredient to infant 98 
formulas. In a recent pilot study (Mehra et al., 2014), a powder enriched in BMO was 99 
produced through a membrane filtration process using mother liquor as a starting material. In 100 
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the current study, this method was used to generate an enriched-BMO powder from 101 
demineralised whey powder, which is an important ingredient in infant formula manufacture. 102 
The powder was further depleted in lactose through size-exclusion chromatography. The final 103 
powder, which was enriched in BMO, was examined for its ability to prevent adhesion of S. 104 
pneumoniae.to respiratory cells using in-vitro assays. 105 
 106 
2. Materials and methods 107 
 108 
2.1.  Materials 109 
 110 
Tissue culture reagents were purchased from Sigma–Aldrich (Wicklow, Ireland) and 111 
LGC (Middlesex, United Kingdom). The oligosaccharides 3′-sialyllactose and 6′-sialyllactose 112 
(3-SL and 6-SL, respectively) were purchased from Carbosynth, Compton, UK. The purity of 113 
both 3-SL and 6-SL is a minimum 98% according to the company’s specification. 114 
 115 
2.2. Enrichment of oligosaccharides 116 
 117 
For enrichment of OS, demineralised whey powder, purchased from Dairygold Co-118 
Operative Society Ltd (Mitchelstown, Ireland), was used in a joint project between Teagasc 119 
and University of California, Davis to enrich OS, according to Mehra et al. (2014). Starting 120 
with demineralised whey powder, which was re-suspended in water to give a final volume of 121 
2428 L at 5% total solids, the process yielded 2.5 kg of milk oligosaccharide-rich powder 122 
(OSP), which was transferred to the Food for Health Ireland consortium and used in the 123 
present study, with the agreement of University California, Davis.  124 
For testing OS in biological assays, OSP was further treated to remove residual 125 
peptides and large levels of lactose. 50 mL of a 20% solution of the OSP was applied to a 126 
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BioGelP2 size exclusion column (Bio-rad Laboratories, Inc., USA; 92 × 5 cm) and eluted 127 
with deionised water at a flow rate of 3 mL min-1. The fractions (14 mL) were analysed for 128 
lactose, 3-SL and 6-SL using high pH anion exchange chromatography with pulsed 129 
amperometric detection (HPAEC-PAD) and peptide concentration (Bradford, 1976). Peptide-130 
free and low-trace lactose fractions (< 80 mg L-1) from 15 runs were pooled and freeze-dried 131 
to give an oligosaccharide-rich fraction (OSF).  132 
 133 
2.3. Quantification of lactose and sialyllactose by high performance liquid 134 
chromatography 135 
 136 
Demineralised whey powder, OSP, OSF and fractions from BioGelP2 were 137 
appropriately diluted in water and analysed for quantification of lactose, 3-SL and 6-SL.  138 
Lactose in demineralised whey powder, OSP and OSF was quantified by high performance 139 
liquid chromatography (HPLC) using an HPX-87C carbohydrate column (300 × 7.8 mm) 140 
(Aminex, Bio-Rad, UK) and a refractive index detector. The elution was obtained in isocratic 141 
conditions using 4.5 mM sulphuric acid for 30 min. 3-SL and 6-SL in all samples above and 142 
lactose in fractions from BioGelP2 were quantified by HPAEC-PAD, according to Mehra et 143 
al. (2014).  144 
 145 
2.4. Structural characterisation of milk oligosaccharides 146 
 147 
The free OS in the OSF were structurally characterised by hydrophobic interaction 148 
liquid chromatography (HILIC) coupled to mass spectrometry by the National Institute for 149 
Bioprocessing Research & Training (NIBRT, Dublin, Ireland) as described by Mariño et al. 150 
(2011). 151 
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 152 
2.5. Organisms and growth conditions 153 
 154 
The S. pneumoniae strain ATCC BAA-255 (S. pneumoniae R6) was obtained from 155 
the American Type Culture Collection. S. pneumoniae R6 was stored in Todd Hewitt broth 156 
(Becton Dickinson and Company, France) containing 10% (v/v) glycerol at –80 °C and 157 
cultured directly from storage into the same broth with 0.5% (w/v) yeast extract (0.2% 158 
inoculum) at 37 °C with 5% CO2 until an optical density (600 nm) of 0.8 was reached. 159 
 160 
2.6. Culture of pneumocytes 161 
 162 
Adherent Detroit 562 (pharynx) and A549 (lung) cells were purchased from the 163 
American Type Culture Collection. These cell lines were chosen because of their routine use 164 
in previous studies (Jensch et al., 2010; Kallio et al., 2014). The Detroit 562 cells were grown 165 
in Eagle’s Minimum Essential Medium (EMEM) supplemented with 10% (v/v) foetal bovine 166 
serum (FBS) and 1% (w/v) of penicillin-streptomycin. The A549 cells were grown in 167 
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% (v/v) of FBS and 168 
1% (w/v) of penicillin-streptomycin. Cells were incubated at 37 °C in an atmosphere of 5% 169 
CO2 and passaged every 3–4 days at ratio 1:6. When the cells were used in the adhesion 170 
assay, they were washed twice with PBS and then incubated with 0.25% trypsin/EDTA 171 
solution. Trypsination was stopped by adding 8–10 mL of fresh antibiotic-free medium. After 172 
seeding cells in 12-well plates to a density of 5 × 105 per well, they were incubated overnight, 173 
and then the spent medium was replaced with 1 mL of DMEM or EMEM supplemented with 174 
2% (v/v) FBS. After a further overnight incubation as described above, the cells were used in 175 
the adhesion assay.  176 
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 177 
2.7.  Adhesion assay 178 
 179 
The adhesion assay used in the present study was adapted from previous publications 180 
(Marotta, Ryan, & Hickey, 2014). Prior to the adhesion assay, confluent monolayers were 181 
treated with 5 µg mL-1 interleukin 1β for 4 h at 37 °C with 5% CO2 to mimic host cell 182 
response during infection (Rosenow et al., 1997). Briefly, 6 mg mL-1 solutions of 183 
demineralised whey powder and OSP were prepared in EMEM supplemented with 2% (v/v) 184 
FBS. Solutions of OSF were prepared at the following concentrations: 6 mg mL-1, 4 mg mL-1, 185 
2.4 mg mL-1, 2 mg mL-1, 1.15 mg mL-1 and 0.24 mg mL-1 (corresponding to 0.3, 0.2, 0.125, 186 
0.1, 0.0575 and 0.0125 mg mL-1 of 6-SL in OSF, respectively) in the appropriate medium 187 
supplemented with 2% FBS (v/v). All solutions were sterilised by filtration. Bacteria were 188 
harvested and re-suspended in tissue culture media with or without OS at 1 × 106 colony 189 
forming units (cfu) mL-1 and incubated for 30 min at 37 °C in an atmosphere of 5% CO2 (pre-190 
incubation step). Controls with no saccharide were also prepared. Confluent monolayers in 191 
12-well plates were washed with PBS, infected with 1 mL of pre-incubated bacteria and 192 
incubated for 30 min at 37 °C with 5% CO2. After 30 min incubation, the wells were washed 193 
three times with PBS to remove any non-adherent bacteria and lysed with 1 mL of PBS 194 
containing 0.2 % (v/v) Triton X-100 (Sigma, Steinheim, Germany) for 30 min at 37 °C on a 195 
shaking platform at 100 agitations per min to ensure maximal recovery of viable bacterial 196 
cells. The lysates were serially diluted and enumerated by spread-plating on sheep blood agar 197 
plates. Aliquots of the experimental inocula were retained, diluted and plated to determine 198 
original cfu mL-1. Agar plates were incubated at 37 °C with 5% CO2 overnight after which 199 
cfu were enumerated. 200 
 201 
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2.7. Bacterial interaction 202 
 203 
In an effort to determine if OS interact with bacteria, the adhesion assay was slightly 204 
modified. S. pneumoniae R6 was grown as described above, re-suspended (1 × 106 cfu mL-1) 205 
in an OSF solution at a concentration of 6 mg mL-1 and 2.4 mg mL-1 when working with 206 
Detroit 562 and A549 cells, respectively, in the appropriate medium supplemented with 2% 207 
FBS (v/v) and incubated for 30 min at 37 °C 5% CO2. The samples were centrifuged at 4000 208 
× g for 7 min to pellet the bacterial cells. The medium containing unbound oligosaccharides 209 
was removed and the bacterial pellet was re-suspended in an equal volume of appropriate 210 
medium. Following this the adhesion assay was performed as described above.  211 
 212 
2.8. Cell line interaction 213 
 214 
To determine if OS mixture interacts with epithelial cells, the adhesion assay was 215 
modified. Confluent monolayers of Detroit 562 and A549 cells were washed with PBS and
 
216 
supplemented with 1 mL of OSF solution at a concentration of 6 mg mL-1 (Detroit 562) and 217 
2.4 mg mL-1 (A549) in the appropriate medium supplemented with 2% FBS (v/v). Controls 218 
were performed in the absence of saccharides. The 12 well plates were incubated at 37 °C 5% 219 
CO2 for 30 min. Following incubation, the 12 well plates were washed 5 times with PBS to 220 
remove the unbound OS. The confluent monolayers were then infected with 1 mL S. 221 
pneumoniae R6 (1 × 106 cfu mL-1) resuspended in the appropriate medium supplemented 222 
with 2% FBS (v/v) and incubated for 30 min. To determine the amount of adhering bacteria 223 
the adhesion assay was performed as described above. 224 
 225 
2.9. Statistical analysis 226 
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 227 
The adhesion assays were carried out on three separate occasions in triplicate. Results 228 
are presented as mean ± standard deviations of replicate experiments. Graphs were drawn 229 
using Microsoft Excel and the unpaired student t-test was used to determine statistically 230 
significant results; P < 0.05 was considered significant.  231 
 232 
3.  Results and discussion 233 
 234 
It is widely accepted that human milk protects and promotes infant health (Gartner et 235 
al., 2005). For instance, human milk plays a major role in protecting infants from respiratory 236 
infections (Duijts, Ramadhani, & Moll, 2009; Wright et al., 1989). Recently, in addition to 237 
IgA, free HMO have been implicated in this protective role, which may be exerted through 238 
direct and/or indirect effects (Stepans et al., 2006). As direct effect, HMO may interfere with 239 
adhesion, by acting as decoys to which pathogens can bind. In the URT, the frequent bathing 240 
in milk might modulate the adherence of bacteria to epithelial cells through the high 241 
concentration of OS present, thereby reducing the incidence of harmful organisms and 242 
lowering the risk of infection (Barthelson et al., 1998). In the lower respiratory tract, OS may 243 
reach the respiratory epithelia through absorption into the blood stream, where they could 244 
influence bacterial-host interactions in a similar manner as observed in the gut. In this 245 
respect, Goehring, Kennedy, Prieto, and Buck (2014) have demonstrated that some ingested 246 
HMO are absorbed intact into the infant circulation. In terms of indirect effects, specific 247 
HMO may have effect on the immune system, as demonstrated by numerous in vitro studies 248 
(Bode et al., 2004a; Bode, Rudloff, Kunz, Strobel, & Klein, 2004b; Eiwegger et al., 2010).  249 
As S. pneumoniae is one of the major bacterial etiological agents of respiratory tract 250 
infections in infants and children, we focused our attention on investigating the effect of a 251 
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pool of oligosaccharides on adhesion of S. pneumoniae on respiratory cells of both the upper 252 
and lower respiratory tract. As human milk is not available for commercial purposes, bovine 253 
milk streams were considered as a suitable source of OS, given their widespread availability.  254 
 255 
3.1. Enrichment of oligosaccharides 256 
 257 
As previously mentioned, concentrations of OS in bovine milk and its streams are 258 
much lower than concentrations of OS found in human milk. For this reason, before testing 259 
the biological properties of BMO, they were extracted and concentrated from demineralised 260 
whey. Demineralised whey was selected as starting material for OS enrichment, because it 261 
contains a higher concentration of sialyllactose (SL, 3'- and 6'- sialyllactose) (47 mg L-1) for 262 
similar lactose concentration (48 g L-1) compared with bovine milk. Furthermore, 263 
demineralised whey is characterized by lower mineral levels, which may be advantageous for 264 
applications in infant formula manufacture, when compared to other bovine streams with 265 
similar SL and lactose concentrations (such as whey permeates). To evaluate enrichment of 266 
OS through the process, SL was selected as a marker of total OS, since it is the predominant 267 
oligosaccharide in the BMO pool and can be quantified by using routine analytical methods.  268 
Following membrane filtration and diafiltration, the diafiltered OS-enriched retentate 269 
had a SL to lactose ratio of 1.65%. This represents a 17-fold enrichment of SL based on the 270 
SL/Lactose ratio. Upon evaporating and spray drying the retentate, 2.5 kg of a powder (OSP) 271 
was obtained with the following composition: 70.21% (w/w) lactose, 1.20% (w/w) SL, 24.5% 272 
(w/w) protein and 4.41 % (w/w) ash. Despite the enrichment of OS compared to the initial 273 
demineralized whey, the major component of the OSP was still lactose. As it has been 274 
previously demonstrated that lactose can interfere with the ability of oligosaccharides to 275 
influence bacterial adhesion (Kavanaugh et al., 2013), to further reduce lactose and 276 
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concentrate OS, the OSP was applied to a size-exclusion chromatography, resulting in 8.83 g 277 
of OSF.  278 
The chromatographic step removed most of the lactose, while retaining approximately 279 
71% of SL (Table 1), resulting in a powder with lactose and SL concentration (ratio 3-SL:6-280 
SL was 3.5:1) of 0.9% and 23% (w/w), respectively. Compared with concentrations found in 281 
whey (0.07%, w/w; Marotta et al. unpublished data), this represents an approximate 329 fold 282 
SL enrichment in the OSF. Recently, nanofiltration was investigated to enrich BMO from 283 
lactose-hydrolysed bovine milk (Altmann et al., 2015) and lactose-hydrolysed colostrum 284 
whey permeate (Cohen, Barile, Liu, & de Moura Bell, 2017). Altmann et al. (2015) produced 285 
a NF retentate containing 873.23 BMO mg L-1. However, the data reported did not allow 286 
calculation of the concentration of BMO as percentage of total solid. Cohen et al. (2017) 287 
produced a NF retentate containing 5.96 SL g L-1, which represented 6.7% of total solids.  288 
Although the process employed in the present study did not hydrolyse lactose and did 289 
not employ NF, as in Altmann et al. (2015) and Cohen et al. (2017), the OSF was 290 
characterised by a much higher content of SL (23%, w/w). The oligosaccharide profile of the 291 
OSF was analysed by NIBRT. After fluorescently labelling with 2-Aminobenzamide (2AB), 292 
the sample was analysed by HILIC. A total of 29 peaks were detected and assigned 293 
comparing the Glucose Unit (GU) values obtained with GU values previously published 294 
(Mariño et al., 2011). Predominant peaks were 3-SL and 6-SL (taken together 55.2% of total 295 
peak area), GalNAc(α1-3)Gal(β1-4)Glc (23.8% of total peak area) followed by Gal(α1-296 
3)Gal(β1-4)Glc (9.6% of total peak area), with latter two not being found in breast milk 297 
(Urashima, Messer & Oftedal, 2017), despite the fact that neutral OS represent the highest 298 
percentage of HMO (Kunz et al., 2000).  299 
In addition, the sample was analysed by HILIC coupled to mass spectrometry for 300 
structural assignment. This allowed the identification of 19 structures, ranging between 300 301 
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and 1200 Da. Five out of 19 structures (3’-fucosyllactose, 3-SL, 6-SL, 6’-sialyllactosamine 302 
and LNnT, which account for a total peak area of 56.52%) are also found in breast milk 303 
(Table 2). Furthermore, using the same analytical technique as Mariño et al. (2011), 4 304 
structures were detected in the OSF, which were not reported in that study and these 305 
included: 3’-fucosyllactose, NeuAc(α2-3)Gal(β1-3)Gal(β1-4)Glc and the O-acelylated forms 306 
of two sialylated oligosaccharides (NeuAc(α2-3)Gal(β1-4)Glc and NeuAc(α2-8)NeuAc(α2-307 
3)Gal(β1-4)Glc). Finally, only a small proportion (0.4% of total peak area) of Neu5Gc was 308 
detected in the OSF, which is particularly important for applications in infant formulas as 309 
Neu5Gc [present in numerous mammals, but not in humans (Varki & Marth, 1995)], is 310 
known to be antigenic (Varki & Schauer, 2009). To the best of our knowledge, this is the first 311 
time that such a well characterised SL-enriched powder, which also contains a variety of 312 
other OS structures, has been produced from commercial dairy streams.  313 
 314 
3.2. Effect of BMO on interaction between respiratory cells and S. pneumoniae 315 
 316 
To determine the concentration of the OSF that should be tested in the in vitro assays, 317 
a number of options were considered such as adding an amount of powder equivalent to the 318 
concentration of HMO (10–15 g L-1). However, as the OSF is not a pure mixture of BMO, a 319 
concentration of BMO corresponding to physiological concentrations of 6-SL, which is a 320 
predominant acidic oligosaccharide in breast milk was selected. Furthermore, previous 321 
studies demonstrated the importance of the α2-6 linkage on interactions with bacteria 322 
(Kavanaugh et al., 2013; Marotta et al., 2014). Marotta et al. (2014) found that 6-SL inhibits 323 
Pseudomonas aeruginosa PAK invasion of pneumocytes. Kavanaugh et al. (2013) 324 
demonstrated that 6-SL increased adhesion of Bifidobacterium longum subsp. infantis ATCC 325 
15697 to HT-29. Consequently, 6-SL was chosen as an indicator of OS concentration and the 326 
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concentration of 6-SL in the OSF was matched to levels of 6-SL found in breast milk (0.1 to 327 
0.3 mg mL-1; Kunz et al., 2000) when tested on pharynx cells. In fact, this is the potential 328 
concentration that an infant’s URT would be exposed to during regular breast feeding.  329 
The OSF significantly reduced the adhesion of S. pneumoniae R6 to the pharynx cells 330 
Detroit 562 by 78%, 51% and 25% at OSF concentrations of 6 mg mL-1 (P<0.001), 4 mg mL-331 
1
 (P<0.001) and 2 mg mL-1 (P<0.001), respectively (Fig. 1). The data demonstrated that the 332 
anti-adhesion effect was concentration dependent with the largest anti-adhesive effect seen at 333 
the highest physiological concentration tested, 0.3 mg mL-1 (Fig. 1). This suggests that the 334 
application of such an OSF should involve the exposure of infants’ URT to reported 335 
physiological range of HMO. In addition the effect of long term exposure to an OSF should 336 
also be considered.  337 
The experiment was repeated testing 6 mg mL-1 solutions of demineralised whey and 338 
OSP, which are the initial and intermediate material prior to OSF production. Solubility 339 
issues meant that higher concentrations could not be tested. In both cases, a minimal (~5%) 340 
and not significant reduction of adhesion was observed (Fig. 2). These results suggest that the 341 
higher levels of OS present in the OSF were responsible for the observed effect. In fact, 342 
demineralised whey, OSP and OSF were tested using the same concentration (6 mg mL-1) of 343 
powder, whereas SL concentration increased from 0.003 mg mL-1 in demineralised whey to 344 
0.072 mg mL-1 in the OSP to a final 0.3 mg mL-1 in the OSF.  345 
The effect of the OSF in reducing the adhesion of S. pneumoniae R6 to the lung cell 346 
line A549 was also investigated. In this case, concentrations of OSF in the range of 0.24 and 347 
2.4 mg mL-1 were used, which correspond to 6-SL concentrations in the range of 0.0125–348 
0.125 mg mL-1. These concentrations were employed for similar studies on P. aeruginosa 349 
(Marotta et al., 2014) and represent the lowest and highest estimated concentration of the 350 
acidic fraction of HMO in infant blood (Bode et al., 2004b), which may potentially reach the 351 
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lungs. The adhesion of S. pneumoniae R6 was significantly reduced by 55, 34 and 17%, 352 
following pre-incubation with the OSF at a concentration of 2.4 mg mL-1 (P < 0.001), 1.15 353 
mg mL-1 (P < 0.001) and 0.24 mg mL-1 (P < 0.005) (Fig. 3). As the powder was re-suspended 354 
in the required media and a control of media alone was included, the effect could be solely 355 
attributed to the OS and not to any component in the media.  356 
The data reported above is in agreement with Barthelson et al. (1998). In that study, 357 
the authors concluded that S. pneumoniae relies to a significant extent upon sialylated 358 
oligosaccharide ligands terminating in NeuAcα2-6(or 3)Galβ1 for adherence to epithelial 359 
cells. The predominance of α2-6 and α2-3 sialylated oligosaccharides in the OSF, which 360 
could act as decoys of the natural receptors of S. pneumoniae, could explain the ability of the 361 
OSF in reducing S. pneumoniae adhesion to respiratory epithelial cells. 362 
As the OSF significantly reduced the adhesion of S. pneumoniae R6 to the pharynx 363 
and lung cells, further studies were carried out to determine if that observed effect was due to 364 
the interaction of the OS with the bacteria or epithelial cells. To determine if OS interacted 365 
with bacteria, the assay was carried out as described, with the removal of unbound OS prior 366 
infection of respiratory epithelial cells. Following the removal of free OS, the adhesion of S. 367 
pneumoniae R6 to pharynx and lung cells was still significantly (P < 0.001) reduced by 77% 368 
and 48%, respectively (Fig. 4). To determine if the OS interacted with the respiratory 369 
epithelial cells, OSF was first incubated with the pharynx and lung cells. Following 30 min 370 
incubation, OS were removed and respiratory epithelial cells were infected with S. 371 
pneumoniae R6. No anti-adhesive effect was observed following this modification to the 372 
adhesion assay (Fig. 4).  373 
The results would indicate that the ability of OS to reduce the adhesion of S. 374 
pneumoniae R6 to epithelial cells of the respiratory tract was mediated by interaction of OS 375 
with the bacteria and not with the epithelial cells, in agreement with results observed by 376 
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Marotta et al. (2014). Furthermore, the results demonstrate that the OSF was not cytotoxic to 377 
respiratory epithelial cells, since the adhesion of bacteria to respiratory epithelial cells alone 378 
and OSF exposed cells was comparable. Furthermore, the viability of the lung cells making 379 
up the confluent monolayer was determined with and without OSF before commencing the 380 
adhesion assays to ensure that OSF was not toxic to the A549 cells. The viability was 381 
approximately 90% (P = 0.27), demonstrating that the growth of the A549 cells was not 382 
affected by the exposure to OSF.  383 
Taken together, the in vitro results reported in the present study suggest that BMO 384 
could be effective in protecting infants from upper and lower respiratory infections associated 385 
to S. pneumoniae. The precise mechanism of how S. pneumoniae establishes and maintains 386 
colonisation has yet to be fully characterised. It is clear, however, that the bacterium’s 387 
glycosidases play a key role in colonisation, as these enzymes are capable of modifying N-388 
linked glycans, O-linked glycans, and glycosaminoglycans on the host epithelial surface, 389 
thereby rendering the host susceptible to colonisation (Bogaert et al., 2004; Tong, Blue, 390 
James, & DeMaria, 2000). For instance, NanA cleaves α2-3- and α2-6-linked sialic acid, 391 
while NanB is specific to α2-3-linked sialic acid (Gut, King, & Walsh, 2008). Furthermore, 392 
BgaA the β-galactosidase is specific to galactose β1-4 linked to N-acetylglucosamine (Galβ1-393 
4GlcNAc), commonly found in complex N-linked glycan structures (King, Hippe, & Weiser, 394 
2006; Zähner & Hakenbeck, 2000; Zeleny, Altmann, & Praznik, 1997). It is the modification 395 
of the host epithelial surface by these glycosidases that is the first step in bacterial 396 
colonisation. As the OSF generated in this study is particularly rich in these structures, it is 397 
possible that the anti-adhesive function is due to a decoy effect as has been previously 398 
suggested in the literature (Hickey, 2012; Morrow, Ruiz-Palacios, Jiang, & Newburg, 2005; 399 
Newburg, 2000).    400 
 401 
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5.  Conclusions 402 
 403 
This study reports the extraction of BMO in gram quantities from whey, employing a 404 
combination of membrane filtration and size-exclusion chromatography. The final product 405 
was characterised not only by the presence of predominant sialyllactose, but also by many 406 
other sialylated and neutral structures. This product was demonstrated to reduce adhesion of 407 
S. pneumoniae to pharynx and lungs cells, when it was tested at different physiological 408 
concentrations. This study further supports the potential production of value-added 409 
ingredients from whey streams, which could be used as functional ingredients in infant 410 
formulas and, more broadly, in foods with health benefits.  411 
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Figure legends 1 
 2 
Fig. 1. Effect of concentration of the oligosaccharide-enriched fraction (OSF) on S. 3 
pneumoniae R6 adhesion to Detroit 562 pharynx cells; control (CNT) was S. pneumoniae R6 4 
in the absence of saccharide. Data are means ± standard deviation of assays carried out on 5 
three separate occasions in triplicate; an asterisk indicates P < 0.001. 6 
 7 
Fig. 2. Effect of different substrates on interaction of S. pneumoniae R6 on pharynx cells. 8 
S. pneumoniae R6 was incubated with 6 mg mL-1 of demineralised whey powder (DWP), 9 
oligosaccharide-enriched powder (OSP) and oligosaccharide-enriched fraction (OSF) in 10 
EMEM supplemented with 2% FBS (v/v); control (CNT) was performed with no saccharide. 11 
Data are means ± standard deviation of assays carried out in triplicate; an asterisk indicates P 12 
< 0.001. 13 
 14 
Fig. 3. Effect of concentration of the OSF on S. pneumoniae R6 adhesion to A549 lung cells; 15 
control (CNT) was S. pneumoniae R6 in the absence of saccharide. Data are means ± 16 
Standard deviation of assays carried out on three separate occasions in triplicate; an asterisk 17 
indicates P < 0.005. 18 
 19 
Fig. 4. Interaction of oligosaccharide-enriched fraction (OSF) with S. pneumoniae R6 () or 20 
with eukaryotic cells (). Left-hand set of data: S. pneumoniae R6 was incubated with 6 mg 21 
mL-1 of OSF in EMEM supplemented with 2% FBS. After incubation the unbound 22 
oligosaccharides were removed before the bacteria were used to infect the pharynx cell (). 23 
Pharynx cells were incubated with 6 mg mL-1 of OSF in the medium above. The unbound 24 
OSF was removed from the pharynx cells, which were subsequently infected with S. 25 
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pneumoniae R6 (). An asterisk indicates P < 0.001. Control (, pharynx cells) was 26 
performed with no saccharide. Right-hand set of data: S. pneumoniae R6 was incubated with 27 
2.4 mg mL-1 of OSF in DMEM supplemented with 2% FBS. After incubation the unbound 28 
oligosaccharides were removed before the bacteria were used to infect the eukaryotic cells 29 
(). Lung cells were incubated with 2.4 mg mL-1 OSF in the above medium. The unbound 30 
OSF was removed from the lung cells, which were subsequently infected with S. pneumoniae 31 
R6 (). An asterisk indicates P < 0.001. Control (CNT, lung cells) was performed with no 32 
saccharide. 33 
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Table 1 
Enrichment of oligosaccharides from OSP employing size exclusion chromatography. a 
Oligosaccharide OSP OSF Yield (%) 
Lactose (g, total) 149.628 0.079 0.05 
SL (g, total) 2.9175 2.084 71.43 
 
a
 Abbreviations are: OSP, oligosaccharides-rich powder; OSF, oligosaccharides-rich fraction. 
Seven hundred and fifty millilitres of OSP were applied over 15 runs and 8.83 g of OSF were 
recovered pooling fractions from the 15 runs. 
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Table 2 
Structural assignment of oligosaccharides in oligosaccharides-rich fraction (OSF). 
Peak 
number 
m/z 
observed 
m/z 
theoretical 
UXOF Symbol structural 
assignment 
GU value Relative 
% 
UPLC-
HILIC-
FLD  
1 
2 
- - monosaccharides 1.00 
1.03 
- 
- 
3 502.22 502.20 
 
 
1.88 0.7 
 
4 
461.21 461.18 
 
 
1.95 
2.5 
5 - - neutral di- or tri-saccharides 2.28 - 
6 
7 
- - acidic di- or tri-saccharides 2.33 
2.36 
0.1 
0.02 
 
8 
 
 
 
607.27 
 
794.32 
 
607.24 
 
794.28 
 
 
2.49  
 
0.7 
9 664.29 664.26 
 
2.71 23.8 
10 664.29 664.26 
 
2.83 1.3 
11 623.26 623.23 
 
 
2.89 1.3 
12 623.26 623.23  
 
2.98 9.6 
 
13 
 
752.31 
 
 
 
623.26 
 
752.27 
 
 
 
623.23 
major component: 
 
 
 
 
minor component: 
 
 
3.15 
 
 
 
47.8 
14 
15 
16 
- - acidic tri- or tetrasaccharides 3.30 
3.34 
3.38 
0.2 
0.1 
0.1 
17 793.35 793.30 
 
3.48 0.7 
18 768.30 768.27 
 
3.50 0.4 
19 752.31 
 
752.27 
 
  
 
 
3.56 
7.4 
20 826.36 826.31 
 
3.63 0.6 
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21 1085.47 1085.38 
 
3.84 0.1 
22 955.39 955.35 
 
3.91 0.3 
23 914.37 914.33 
 
4.01 1.3 
24 - - acidic oligosaccharide 4.11 0.03 
25 914.37 914.33 
 
4.33 0.2 
 
 
26 
1043.44 1043.37 
  
 
 
4.58 
0.4 
27 1029.45 1029.39 
 
4.69 - 
 
28 
988.43 988.36 
 
 
4.84 
0.1 
29 - - acidic oligosaccharide 5.47 0.2 
 
a
 Relative % UPLC-HILIC-FLD represents area of peaks compared with total peak area in 
HILIC chromatograms. Symbols are: , N-acetylglucosamine; , glucose; , galactose; , 
N-acetylgalactosamine; , fucose; , mannose; , N-acetylneuraminic acid; , N-
glycolylneuraminic acid; , xylose. Linkages are denoted as: ---, α-linkage; —,β-linkage.  
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Figure 4.  
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